WALTHAM, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, invites investors and the general public to listen to a webcast of an investor briefing scheduled for Sunday, June 1 at 6:15 PM Central time in conjunction with the 2014 American Society of Clinical Oncology (ASCO) annual meeting. At this briefing, TESARO management will review rolapitant clinical data, discuss the niraparib development strategy and provide an update on its TSR-011 and immuno-oncology programs. In addition, Jeffrey Patton, M.D. of Tennessee Oncology, a practicing oncologist with extensive experience in the treatment of patients with a variety of cancers, and Drew Pardoll, M.D., Ph.D. of Johns Hopkins University, an expert in immuno-oncology approaches such as those targeting PD-1, TIM-3, LAG-3 and other immune regulators, will take part in discussions with investors.
Help employers find you! Check out all the jobs and post your resume.
